BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today provided a business update and announced it has completed screening for enrollment in the pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity.

ICON plc today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST.

Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline and plans for 2024 during Enanta’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT.

SimBioSys today it has received its first U.S. Food and Drug Administration (FDA) 510(k) clearance to market its first software application on its cloud-based digital precision medicine platform, TumorSight™.

Xeris Biopharma Holdings, Inc. today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2023.

ROME Therapeutics today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.

Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND.

Alex Therapeutics and Vicore Pharma announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital cognitive behavioral therapy intervention accessed through a smartphone or tablet.

GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held in San Francisco, California, USA, from January 8 to 11, 2024.

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference.